PYXS

Pyxis Oncology Inc

Add to Watchlist

Advanced Chart

1.240

+0.01(0.813%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.250

Open

1.220

VWAP

1.23

Vol

266.50K

Mkt Cap

76.90M

Low

1.200

Amount

327.90K

EV/EBITDA(TTM)

Total Shares

58.89M

-11.98M

EV/OCF(TTM)

P/S(TTM)

26.92

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.357

+1.91%

-0.302

+15.18%

-0.346

-1.14%

Estimates Revision

The market is revising No Change the revenue expectations for Pyxis Oncology, Inc. (PYXS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 0.81%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+0.81%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast PYXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYXS is 6.67 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 1.240

Low

5.00

Averages

6.67

High

8.00

Current: 1.240

Low

5.00

Averages

6.67

High

8.00

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-03-19

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-19

Reiterates

Strong Buy

Reason

RBC Capital

Leonid Timashev

Buy

Reiterates

2025-03-19

Reason

RBC Capital

Leonid Timashev

Price Target

2025-03-19

Reiterates

Buy

Reason

RBC Capital

Leonid Timashev

Buy

Reiterates

$10 → $8

2024-12-20

Reason

RBC Capital

Leonid Timashev

Price Target

$10 → $8

2024-12-20

Reiterates

Buy

Reason

RBC Capital analyst Leonid Timashev lowered the firm's price target on Pyxis Oncology to $8 from $10 and keeps an Outperform rating on the shares. The company's pipeline update to prioritize PYX-201 over further investment in PYX-106 is "prudent" given the early signs of activity and the operating expense savings that will be leveraged to continue to advance PYX-201 development, though the firm is reducing its price target on lower "pipeline optionality", the analyst tells investors in a research note.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$7 → $5

2024-12-20

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$7 → $5

2024-12-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2024-11-21

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2024-11-21

Reiterates

Strong Buy

Reason

William Blair

Andy Hsieh

Buy

Hold

Downgrades

n/a

2024-11-21

Reason

William Blair

Andy Hsieh

Price Target

n/a

2024-11-21

Downgrades

Buy

Hold

Reason

William Blair analyst Andy Hsieh downgraded Pyxis Oncology to Market Perform from Outperform.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pyxis Oncology Inc (PYXS.O) is -0.92, compared to its 5-year average forward P/E of -1.89. For a more detailed relative valuation and DCF analysis to assess Pyxis Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.89

Current PE

-0.92

Overvalued PE

-0.29

Undervalued PE

-3.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.19

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.46

Undervalued EV/EBITDA

-1.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

73.45

Current PS

0.00

Overvalued PS

230.01

Undervalued PS

-83.11